Akcea Reports Financial Results and Highlights for Second Quarter 2020
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/22/2026
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Applied Optoelectronics sets up $600M at-the-market stock offering
- Fannie Mae loses at least 10 senior executives amid departures - WSJ
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- One killed, three injured when man attacks Swedish school with sword
- Morgan Stanley course-corrects their semiconductor equipment outlook on demand
Akcea Therapeutics (AKCA) Misses Q2 EPS by 14c
August 4, 2020 4:42 PM EDTAkcea Therapeutics (NASDAQ: AKCA) reported Q2 EPS of ($0.49), $0.14 worse than the analyst estimate of ($0.35). Revenue for the quarter came in at $22 million versus the consensus estimate of $30.93 million.
"We achieved important commercial milestones during the second quarter and continued to see consistent revenue growth with both... More
